



For further information:
Marta Campos Martínez
mcampos@rovi.es
Tel: +34 91 244 44 22

ROVI will market TEVA's osteoporosis treatment for adults Tetridar[®] (teriparatide) in Spain

- This injectable medicine is used to stimulate bone formation and increase bone strength, thus reducing the risk of fracture
- ROVI is expected to begin the marketing of Tetridar[®] in this country in the third quarter of 2019
- Since it is a molecule developed by chemical synthesis the original of which is a biological product, it helps to significantly reduce patient hypersensitivity to the treatment

Madrid, 11 April, 2019 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI) will market Teva Pharmaceutical Industries Ltd. (TEVA)'s medicine Tetridar[®] (teriparatide) for the treatment of osteoporosis in adults in Spain.

Tetridar[®], an injection containing the active substance teriparatide, is used to increase bone strength and reduce the risk of fracture by stimulating bone formation.

Marketing of this pharmaceutical by ROVI is expected to commence in the third quarter of 2019. Under the agreement between the two companies, ROVI will be responsible for the promotion and distribution of Tetridar[®] in Spanish territory for a five-year period as of the date on which marketing commences, which may subsequently be extended for a further five years.

Juan López-Belmonte Encina, CEO of ROVI, says, "*This new agreement pursues our permanent goal of enhancing the quality of life of patients. Likewise, we hope this product will help to reinforce our product portfolio in the pharmaceutical specialties area*".

Carlos Teixeira, TEVA's General Manager, highlights Tetridar®'s potential: *"This medicine allows patient hypersensitivity to the treatment to be reduced considerably, since it is a molecule developed by chemical synthesis the original of which is a biological product"*.

Osteoporosis is a disease that weakens bones and makes them fragile. This disease is especially frequent in post-menopausal women, but may also affect men. In addition, osteoporosis often occurs in patients treated with corticosteroids.

According to the data of the specialised healthcare management consultant Iqvia, in the twelve months up to February 2019 (MAT February 2019), sales of the original teriparatide molecule in Spain totalled 69.2 million euros.

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy France and Poland, and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is already marketed in 56 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its in-house developed enoxaparin biosimilar in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es

About TEVA

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way.

Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com